Date: 2012-11-06
Type of information: Licensing agreement
Compound: cell line derived from Vivalis’ proprietary EB66® technology platform for the production of animal health vaccines
Company: Vivalis (France), Kyoto Biken Laboratories (Japan)
Therapeutic area: Veterinary medicine
Type agreement: licensing
Action mechanism:
Disease:
Details: Vivalis has signed new research license with Kyoto Biken Laboratories, based in Japan, for a cell line derived from Vivalis’ proprietary EB66® technology platform for the production of animal health vaccines.
Kyoto Biken currently maintains a commercial license agreement to the EB66® cell line for the production of poultry vaccines.To date, over 30 agreements have been signed for the use of the EB66® technology platform for the production of both human and animal health biologics, including vaccines and recombinant proteins.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
